AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31091322 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EAc)
Number of subjects: 52
Study 31091322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham Electroacupuncture (ShEAc)
Number of subjects: 52
Study 31091322 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 52
Study 31337342 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 900 mg/m2 on Days 1 and 8, and docetaxel 70 mg/m2 on Day 8 in 3-week cycles until disease progression or treatment failure.
Number of subjects: 20
Study 28168925 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull energy drink 250 mL
Number of subjects: 24
Study 28168925 — intervention group
Group type: COMPARATOR
Intervention: Red Bull Sugarfree energy drink 250 mL
Number of subjects: 24
Study 28168925 — intervention group
Group type: COMPARATOR
Intervention: Placebo 250 mL
Number of subjects: 24
Study 25639864 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by adjuvant radiotherapy (S arm)
Number of subjects: 119
Study 25639864 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) (C arm)
Number of subjects: 119
Study 23992525 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth periodontal scaling and root planing during a single visit
Number of subjects: 273
Study 23992525 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 273
Study 21555229 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention with graphic material for postoperative pain management
Number of subjects: 497
Study 21555229 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard training on surgical and postoperative recommendations
Number of subjects: 497
Study 19636715 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial rejection images
Number of subjects: 35
Study 19636715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonracial positive images
Number of subjects: 35
Study 19636715 — intervention group
Group type: COMPARATOR
Intervention: Racial acceptance images
Number of subjects: 35
Study 19636715 — intervention group
Group type: COMPARATOR
Intervention: Nonracial negative images
Number of subjects: 35
Study 16396865 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) group (> or =30 seconds from moment of delivery)
Number of subjects: 46
Study 16396865 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (ECC) group with conventional management
Number of subjects: 46
Study 16396865 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) for vaginal deliveries
Number of subjects: 46
Study 16396865 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) for cesarean deliveries
Number of subjects: 46
Study 12694429 — intervention group
Group type: EXPERIMENTAL
Intervention: NK 10% gel
Number of subjects: 45
Study 12694429 — intervention group
Group type: EXPERIMENTAL
Intervention: NK 5% gel
Number of subjects: 45
Study 12694429 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 45
Study 11028477 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/kg of bFGF
Number of subjects: 19
Study 11028477 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg/kg of bFGF once
Number of subjects: 19
Study 11028477 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg/kg of bFGF on two consecutive days
Number of subjects: 19
Study 11028477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8870539 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0
Study 8870539 — intervention group
Group type: COMPARATOR
Intervention: Medications
Number of subjects: 0
Study 1643700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous idarubicin (12 mg/m2)
Number of subjects: 21
Study 1643700 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral idarubicin (30-35 mg/m2)
Number of subjects: 21
Study 6433636 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (median dose 31 mg/kg/day)
Number of subjects: 29
Study 6433636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29086030 — intervention group
Group type: EXPERIMENTAL
Intervention: New equations for predicting resting energy expenditure (REE) developed from Group 1 (n=174)
Number of subjects: 330
Study 29086030 — intervention group
Group type: EXPERIMENTAL
Intervention: New equations for predicting resting energy expenditure (REE) generated from Group 2 (n=115)
Number of subjects: 330
Study 29086030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation of equations using Group 3 (n=41)
Number of subjects: 330
Study 29086030 — intervention group
Group type: COMPARATOR
Intervention: Comparison with other REE prediction equations
Number of subjects: 330
Study 27441478 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose melatonin treatment group (10mg capsule once daily)
Number of subjects: 45
Study 27441478 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose melatonin treatment group (20mg capsule once daily)
Number of subjects: 45
Study 27441478 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled group
Number of subjects: 45
Study 25240493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 30
Study 25240493 — intervention group
Group type: COMPARATOR
Intervention: Control (no AF detected)
Number of subjects: 30
Study 21630255 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected specimens using Cervista (Hologic)
Number of subjects: 8556
Study 21630255 — intervention group
Group type: COMPARATOR
Intervention: Endocervical specimens using Cervista (Hologic)
Number of subjects: 8556
Study 21630255 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected specimens using MALDI-TOF
Number of subjects: 8556
Study 21630255 — intervention group
Group type: COMPARATOR
Intervention: Endocervical specimens using MALDI-TOF
Number of subjects: 8556
Study 19926386 — intervention group
Group type: EXPERIMENTAL
Intervention: Real time automated feedback
Number of subjects: 0
Study 19926386 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR without feedback
Number of subjects: 0
Study 17669347 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-analytical parameters affecting proteomic analysis
Number of subjects: 0
Study 16214452 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of magnesium intake (median 433 mg/day)
Number of subjects: 39876
Study 12120887 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed (Tomudex)
Number of subjects: 25
Study 12120887 — intervention group
Group type: COMPARATOR
Intervention: Nordic FLv regimen
Number of subjects: 25
Study 12120887 — intervention group
Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 25
Study 9734735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion
Number of subjects: 8
Study 9734735 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal saline infusion
Number of subjects: 8
Study 9734735 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of octreotide
Number of subjects: 8
Study 8295285 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril, 50 mg, twice per day
Number of subjects: 92
Study 8295285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 2738792 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination diet with double-blind, placebo-controlled oral food challenges
Number of subjects: 75
Study 2738792 — intervention group
Group type: EXPERIMENTAL
Intervention: Second rechallenge after 2 years
Number of subjects: 75
Study 2738792 — intervention group
Group type: EXPERIMENTAL
Intervention: Third rechallenge
Number of subjects: 75
Study 2738792 — intervention group
Group type: EXPERIMENTAL
Intervention: Major allergens (egg, milk, soy, wheat, peanut)
Number of subjects: 75
Study 2738792 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at diagnosis
Number of subjects: 75
Study 2738792 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum IgE and prick skin tests
Number of subjects: 75
Study 2738792 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin test wheal size
Number of subjects: 75
Study 2738792 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial challenge with skin symptoms
Number of subjects: 75
Study 1092728 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg naproxen daily
Number of subjects: 50
Study 1092728 — intervention group
Group type: COMPARATOR
Intervention: 100 mg indomethacin daily
Number of subjects: 50
Study 31274533 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation in serodiscordant partnerships
Number of subjects: 0
Study 31274533 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention of PrEP initiation and retention
Number of subjects: 0
Study 31274533 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention interventions
Number of subjects: 0
Study 31274533 — intervention group
Group type: COMPARATOR
Intervention: Controlled setting with randomly selected PrEP initiators
Number of subjects: 0
Study 28689520 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin 12-hour therapy (Group-B)
Number of subjects: 90
Study 28689520 — intervention group
Group type: COMPARATOR
Intervention: Terlipressin 72-hour therapy (Group-A)
Number of subjects: 90
Study 25677353 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioral therapy (CBT)
Number of subjects: 152
Study 25677353 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 152
Study 25038208 — intervention group
Group type: EXPERIMENTAL
Intervention: LOLA
Number of subjects: 124
Study 25038208 — intervention group
Group type: EXPERIMENTAL
Intervention: rifaximin
Number of subjects: 124
Study 25038208 — intervention group
Group type: EXPERIMENTAL
Intervention: probiotics
Number of subjects: 124
Study 25038208 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 124
Study 22996863 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical pain-visual analog scale (VAS)
Number of subjects: 40
Study 22996863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasantness-visual analog scale (VAS)
Number of subjects: 40
Study 22996863 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials (SEPs)
Number of subjects: 40
Study 19942034 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-patient simulation experiences
Number of subjects: 0
Study 17563155 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-statements (anxious self-talk)
Number of subjects: 145
Study 17563155 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for anxiety disorders (AD)
Number of subjects: 145
Study 17563155 — intervention group
Group type: EXPERIMENTAL
Intervention: States of mind ratio
Number of subjects: 145
Study 17563155 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive and depressive cognitions
Number of subjects: 145
Study 15702530 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine practice of gastrointestinal surgery
Number of subjects: 379
Study 15702530 — intervention group
Group type: COMPARATOR
Intervention: University hospitals
Number of subjects: 379
Study 11544612 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 33
Study 11544612 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 33
Study 9625683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol, 300 mg twice daily (or 300 mg in the morning and 600 mg in the evening if body weight was > 90 kg)
Number of subjects: 67
Study 9625683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 9625683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol
Number of subjects: 67
Study 7839475 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled racemic epinephrine
Number of subjects: 0
Study 7839475 — intervention group
Group type: EXPERIMENTAL
Intervention: L-epinephrine
Number of subjects: 0
Study 7839475 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (greater than 0.6 mg/kg)
Number of subjects: 0
Study 7839475 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids (when intubation is necessary)
Number of subjects: 0
Study 3203714 — intervention group
Group type: EXPERIMENTAL
Intervention: Emthexat 2.5 mg tablets
Number of subjects: 39
Study 3203714 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 2.5 mg tablets
Number of subjects: 39
Study 2197851 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g protein with 50 g glucose
Number of subjects: 7
Study 2197851 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g protein with 50 g glucose
Number of subjects: 7
Study 2197851 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g protein with 50 g glucose
Number of subjects: 7
Study 2197851 — intervention group
Group type: COMPARATOR
Intervention: 50 g glucose alone
Number of subjects: 7
Study 2197851 — intervention group
Group type: EXPERIMENTAL
Intervention: Various amounts of protein with 50 g glucose
Number of subjects: 7
Study 1096575 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil
Number of subjects: 16
Study 1096575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1096575 — intervention group
Group type: COMPARATOR
Intervention: L-DOPA
Number of subjects: 16
Study 31739206 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial orthosis
Number of subjects: 24
Study 31739206 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made orthosis
Number of subjects: 24
Study 30673020 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics (chlorthalidone/amiloride)
Number of subjects: 110
Study 30673020 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 110
Study 28431534 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina platensis (500 mg, twice daily)
Number of subjects: 64
Study 28431534 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch pills, two daily)
Number of subjects: 64
Study 26382243 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD-80 pacing for 3 months
Number of subjects: 12
Study 26382243 — intervention group
Group type: COMPARATOR
Intervention: DDD-60 pacing for 3 months
Number of subjects: 12
Study 24940324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac sodium 75mg
Number of subjects: 42
Study 24940324 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 42
Study 21701422 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic EGF treatment initiated immediately after pneumonia onset
Number of subjects: 0
Study 21701422 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic EGF treatment initiated 24 hours after pneumonia onset
Number of subjects: 0
Study 21701422 — intervention group
Group type: COMPARATOR
Intervention: Transgenic IFABP-EGF mice
Number of subjects: 0
Study 21701422 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 19298949 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral participants generating properties for noun phrases
Number of subjects: 0
Study 19298949 — intervention group
Group type: COMPARATOR
Intervention: Participants instructed to describe images
Number of subjects: 0
Study 19298949 — intervention group
Group type: COMPARATOR
Intervention: Participants instructed to produce word associations
Number of subjects: 0
Study 17200252 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin infusion (0.5 U/kg per hour)
Number of subjects: 201
Study 17200252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 15482873 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention including enforcement of regulations, education, and peer review in Hanoi and Bangkok.
Number of subjects: 146
Study 15482873 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer review in Hanoi and Bangkok after the intervention.
Number of subjects: 146
Study 15482873 — intervention group
Group type: COMPARATOR
Intervention: Regulatory intervention in Bangkok.
Number of subjects: 146
Study 15482873 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer review in Bangkok after the intervention.
Number of subjects: 146
Study 11517129 — intervention group
Group type: EXPERIMENTAL
Intervention: ECWO plus CPAP (5)
Number of subjects: 19
Study 11517129 — intervention group
Group type: COMPARATOR
Intervention: ECWO plus CPAP
Number of subjects: 19
Study 9932161 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHF (100 mg/m2 days 1-5 i.v. bolus) plus FU (400 mg/m2 days 1-5) given as i.v. bolus injection
Number of subjects: 82
Study 9932161 — intervention group
Group type: COMPARATOR
Intervention: MTHF (100 mg/m2 days 1-5 i.v. bolus) plus FU (400 mg/m2 days 1-5) given as a two-hour infusion
Number of subjects: 82
Study 7832178 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategy 1
Number of subjects: 0
Study 7832178 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategy 2
Number of subjects: 0
Study 7832178 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategy 3
Number of subjects: 0
Study 7832178 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategy 4
Number of subjects: 0
Study 7832178 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategy 5
Number of subjects: 0
Study 7832178 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategy 6
Number of subjects: 0
Study 3403864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cottonseed flour (double-blind, placebo-controlled food challenge)
Number of subjects: 7
Study 3403864 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blind, placebo-controlled food challenge)
Number of subjects: 7
Study 31625596 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped wedge cluster randomized trials with varying cluster sizes
Number of subjects: 0
Study 31625596 — intervention group
Group type: COMPARATOR
Intervention: Stepped wedge cluster randomized trials with equal cluster sizes
Number of subjects: 0
Study 29889748 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol and 100 mg progesterone
Number of subjects: 1845
Study 29889748 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg estradiol and 100 mg progesterone
Number of subjects: 1845
Study 29889748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1845
Study 29889748 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg estradiol and 50 mg progesterone
Number of subjects: 1845
Study 29889748 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg estradiol and 50 mg progesterone
Number of subjects: 1845
Study 26983396 — intervention group
Group type: EXPERIMENTAL
Intervention: LM + 30 g/day brown milled flaxseed for 12 weeks
Number of subjects: 50
Study 26983396 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification (LM)
Number of subjects: 50
Study 24731416 — intervention group
Group type: EXPERIMENTAL
Intervention: UPPP with oral appliance (UA group)
Number of subjects: 30
Study 24731416 — intervention group
Group type: COMPARATOR
Intervention: UPPP only (U group)
Number of subjects: 30
Study 22614152 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (0.1 to 0.30 mg/kg/day)
Number of subjects: 9
Study 20375709 — intervention group
Group type: EXPERIMENTAL
Intervention: H5N1 vaccine (1.9 microg HA/AS03(B), 3.75 microg HA/AS03(B), and 3.75 microg HA/AS03(A))
Number of subjects: 51
Study 20375709 — intervention group
Group type: COMPARATOR
Intervention: TIV
Number of subjects: 51
Study 20375709 — intervention group
Group type: EXPERIMENTAL
Intervention: H5N1 vaccine
Number of subjects: 51
Study 17656620 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 25, 50, 100, and 200 mg
Number of subjects: 44
Study 17656620 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg with high-fat meal
Number of subjects: 44
Study 15767179 — intervention group
Group type: COMPARATOR
Intervention: Axillary lymphadenectomy with drains
Number of subjects: 0
Study 15767179 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymphadenectomy without drains
Number of subjects: 0
Study 11824859 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP-V1-antagonist (d(CH2)5Tyr(me)AVP; 0.5 mg; AVPi)
Number of subjects: 10
Study 11824859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10472321 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of guidelines for occupational rehabilitation
Number of subjects: 59
Study 8678512 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU and leucovorin
Number of subjects: 0
Study 8678512 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU and levamisole
Number of subjects: 0
Study 8678512 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone or in combination with chemotherapeutic drugs
Number of subjects: 0
Study 1855676 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy using a combination of 1:100,000 adrenaline and 5% ethanolamine
Number of subjects: 109
Study 1855676 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 109
Study 1855676 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy after rebleeding in conservatively treated group
Number of subjects: 109
Study 6661730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic drugs (physostigmine, pyridostigmine bromide, edrophonium chloride)
Number of subjects: 0
Study 6661730 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic drugs (scopolamine, orphenadrine)
Number of subjects: 0
Study 6661730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28425183 — intervention group
Group type: EXPERIMENTAL
Intervention: Teens experiencing 4+ major life events
Number of subjects: 178
Study 28425183 — intervention group
Group type: COMPARATOR
Intervention: Fewer major life events
Number of subjects: 178
Study 27465213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (n = 231)
Number of subjects: 464
Study 27465213 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (n = 233)
Number of subjects: 464
Study 27465213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 464
Study 27465213 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 464
Study 24154560 — intervention group
Group type: EXPERIMENTAL
Intervention: vibroX (n = 11)
Number of subjects: 21